Overview of China's Market Approval Policy Med Insurance Payment System

Rare disease patients in China face many challenges. Rare diseases can be challenging to diagnose. Even when patients are diagnosed, they cannot get access to efficacious treatment as there are no available drugs in China, or the approved drugs are not intended for rare disease treatments. Moreover, patients cannot afford approved drugs due to their lack of reimbursement coverage. Among them, inaccessibility and unaffordability are the most prominent causes, making more than half of patients unable to receive timely and sufficient treatment.

In this whitepaper, hear from Parexel rare disease consultants on the following topics:

  • Relevant Policies on Expedited Approval of Rare Disease Drugs 
  • An Overview of China’s Multi-Layered Reimbursement System for Rare Disease Drugs

Open PDF

Return to Insights Center

Related Insights


New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023


Why Rare Disease Therapeutics Need Early Market Access Planning

Jan 4, 2023


China's Market Approval Policy and Medical Insurance Payment System for Rare Disease

Jul 21, 2022


Three strategies for articulating a coherent product value story

Dec 18, 2021


Pragmatic Trials: Targeting evidence generation to inform market access and meet payers’ needs

Feb 8, 2022


How biotechs can strengthen their value story with advanced analytics

Feb 15, 2022


Parexel names first Patient Ambassador

Jun 17, 2022


EU Orphan Drug Designation – overcoming regulatory challenges

Jul 20, 2022


Reimbursement framework for medical devices in India

Mar 7, 2023


Preparing for a new era in European Market Access

Jul 22, 2022


Rachel Smith joins Parexel as Executive Director and Head of the Rare Disease, Center of Excellence

Aug 10, 2022


U.S. price reforms 2022: How can drug manufacturers best prepare for the Inflation Reduction Act?

Aug 17, 2022